BACKGROUND: The tachykinin receptor 1 (TACR1) gene is a promising candidate gene in the search for the genetic basis of alcohol dependence (AD); TACR1 antagonists improve symptomology not only in preclinical models of AD but also in a clinical sample of detoxified alcoholics (George et al., Science 319:1536, 2008). The purpose of the current study was to determine whether TACR1 single nucleotide polymorphisms (SNPs) were associated with (i) blood oxygen level dependent (BOLD) activation in response to gustatory alcohol cues in a sample of heavy drinkers and (ii) Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) AD symptom count in a large, publicly available data set-the Study of Addictions: Genetics and Environment Genome Wide Association study (SAGE GWAS) (Bierut et al., 2010). METHODS: First, we examined relationships between TACR1 genotypes and neural responses during a craving task in 326 individuals with alcohol use disorders. Next, correlational analyses between 69 TACR1 SNPs and DSM-IV-TR AD symptoms were performed on the SAGE data set. RESULTS: rs3771863, rs3755459, and rs1106855 predicted BOLD activation in response to alcohol cues in those same reward and reinforcement brain areas, especially in the medial prefrontal cortex, striatum, and insula. rs3771863 also predicted AD symptom count in the SAGE data set and BOLD activation in the mesocorticolimbic pathway response to alcohol cues. CONCLUSIONS: Each of the 5 SNPs in the TACR1 gene that was significantly related to AD severity in the SAGE data set and/or the BOLD response to the craving task is near the 3' or 5' areas of the gene and may therefore be near mutations with potential functional significance. In particular, the potential functional significance of rs1106855 should be explored because of its location within a stop codon.
RCT Entities:
BACKGROUND: The tachykinin receptor 1 (TACR1) gene is a promising candidate gene in the search for the genetic basis of alcohol dependence (AD); TACR1 antagonists improve symptomology not only in preclinical models of AD but also in a clinical sample of detoxified alcoholics (George et al., Science 319:1536, 2008). The purpose of the current study was to determine whether TACR1 single nucleotide polymorphisms (SNPs) were associated with (i) blood oxygen level dependent (BOLD) activation in response to gustatory alcohol cues in a sample of heavy drinkers and (ii) Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) AD symptom count in a large, publicly available data set-the Study of Addictions: Genetics and Environment Genome Wide Association study (SAGE GWAS) (Bierut et al., 2010). METHODS: First, we examined relationships between TACR1 genotypes and neural responses during a craving task in 326 individuals with alcohol use disorders. Next, correlational analyses between 69 TACR1 SNPs and DSM-IV-TR AD symptoms were performed on the SAGE data set. RESULTS:rs3771863, rs3755459, and rs1106855 predicted BOLD activation in response to alcohol cues in those same reward and reinforcement brain areas, especially in the medial prefrontal cortex, striatum, and insula. rs3771863 also predicted AD symptom count in the SAGE data set and BOLD activation in the mesocorticolimbic pathway response to alcohol cues. CONCLUSIONS: Each of the 5 SNPs in the TACR1 gene that was significantly related to AD severity in the SAGE data set and/or the BOLD response to the craving task is near the 3' or 5' areas of the gene and may therefore be near mutations with potential functional significance. In particular, the potential functional significance of rs1106855 should be explored because of its location within a stop codon.
Authors: Eric D Claus; Sarah W Feldstein Ewing; Francesca M Filbey; Amithrupa Sabbineni; Kent E Hutchison Journal: Neuropsychopharmacology Date: 2011-06-15 Impact factor: 7.853
Authors: Jesse R Schank; Charles L Pickens; Kelly E Rowe; Kejun Cheng; Annika Thorsell; Kenner C Rice; Yavin Shaham; Markus Heilig Journal: Psychopharmacology (Berl) Date: 2011-02-22 Impact factor: 4.530
Authors: Andreas Heinz; Jana Wrase; Thorsten Kahnt; Anne Beck; Zohra Bromand; Sabine M Grüsser; Thorsten Kienast; Michael N Smolka; Herta Flor; Karl Mann Journal: Alcohol Clin Exp Res Date: 2007-05-04 Impact factor: 3.455
Authors: David T George; Jodi Gilman; Jacqueline Hersh; Annika Thorsell; David Herion; Christopher Geyer; Xiaomei Peng; William Kielbasa; Robert Rawlings; John E Brandt; Donald R Gehlert; Johannes T Tauscher; Stephen P Hunt; Daniel Hommer; Markus Heilig Journal: Science Date: 2008-02-14 Impact factor: 47.728
Authors: Francesca M Filbey; Lara Ray; Andrew Smolen; Eric D Claus; Amy Audette; Kent E Hutchison Journal: Alcohol Clin Exp Res Date: 2008-07 Impact factor: 3.455
Authors: Jesse R Schank; Courtney E King; Hui Sun; Kejun Cheng; Kenner C Rice; Markus Heilig; David Weinshenker; Jason P Schroeder Journal: Neuropsychopharmacology Date: 2013-10-31 Impact factor: 7.853
Authors: S C Warner; D A Walsh; L L Laslett; R A Maciewicz; A Soni; D J Hart; W Zhang; K R Muir; E M Dennison; P Leaverton; E Rampersaud; C Cooper; T D Spector; F M Cicuttini; N K Arden; G Jones; M Doherty; A M Valdes Journal: Eur J Pain Date: 2017-05-11 Impact factor: 3.931
Authors: Britta S Nelson; Hannah D Fulenwider; Sadie E Nennig; Britessia M Smith; Michelle K Sequeira; Scott H Chimberoff; Christopher T Richie; Kejun Cheng; Kenner C Rice; Brandon K Harvey; Markus Heilig; Jesse R Schank Journal: Neuroscience Date: 2019-06-23 Impact factor: 3.590
Authors: Ozgun Gokce; Geoffrey M Stanley; Barbara Treutlein; Norma F Neff; J Gray Camp; Robert C Malenka; Patrick E Rothwell; Marc V Fuccillo; Thomas C Südhof; Stephen R Quake Journal: Cell Rep Date: 2016-07-14 Impact factor: 9.423